Ciprofloxacin (Cipro, BAYQ3939)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Infection
Conditions
Pseudomonas Infection
Trial Timeline
Jul 1, 2009 → Oct 1, 2010
NCT ID
NCT00910351About Ciprofloxacin (Cipro, BAYQ3939)
Ciprofloxacin (Cipro, BAYQ3939) is a phase 1 stage product being developed by Bayer for Pseudomonas Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00910351. Target conditions include Pseudomonas Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01561794 | Phase 3 | Completed |
| NCT00910351 | Phase 1 | Completed |
Competing Products
8 competing products in Pseudomonas Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| tobramycin + tobramycin | Novartis | Phase 3 | 77 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 77 |
| TIS or TIP | Novartis | Approved | 85 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 74 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 20 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 60 |